ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline has inked a deal with ChemoCentryx to discover and commercialize small-molecule drugs targeting four chemokine and chemoattractant receptors for the treatment of inflammatory diseases. ChemoCentryx will receive a $63.5 million up-front payment, as well as research funding and potential milestone payments worth up to $1.5 billion, if all six product options across the four targets reach the market. GSK will also invest in ChemoCentryx upon an initial public offering of the biotech firm. In addition, the deal gives GSK access to ChemoCentryx's lead drug candidate, Traficet-EN, which is in late-stage trials for treatment of inflammatory bowel disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter